Neuronal TLR9 signalling crucial for memory formation
Nature Reviews Immunology, Published online: 17 April 2024; doi:10.1038/s41577-024-01034-4Neuronal TLR9 signalling crucial for memory formation
Publicaciones
Neuropilin-1<sup>high</sup> monocytes protect against neonatal inflammation
Cellular & Molecular Immunology, Published online: 17 April 2024; doi:10.1038/s41423-024-01157-7Neuropilin-1high monocytes protect against neonatal inflammation
Bypassing PELO-mediated ATPase activation of the NLR is a common pathogenic cause of <i>NLR</i>-associated autoinflammatory diseases
Cellular & Molecular Immunology, Published online: 17 April 2024; doi:10.1038/s41423-024-01162-wBypassing PELO-mediated ATPase activation of the NLR is a common pathogenic cause of NLR-associated autoinflammatory diseases
Targeting macrophage metabolism to enhance tumor immunotherapy
Cellular & Molecular Immunology, Published online: 17 April 2024; doi:10.1038/s41423-024-01149-7Targeting macrophage metabolism to enhance tumor immunotherapy
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer
Background
Natural killer (NK) cells are cytotoxic cells capable of recognizing heterogeneous cancer targets without prior sensitization, making them promising prospects for use in cellular immunotherapy. Companion dogs develop spontaneous cancers in …
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Yet, only half of the early responders will continue to be disease-free by 12 months, and r…
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune checkp…
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma
Background
Approximately two-thirds of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) do not respond to or relapse after anti-CD19 chimeric antigen receptor T (CAR T)-cell therapy, leading to poor outcomes. Previous studies have…
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Background
Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently under…